These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15623650)

  • 1. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
    Yen WC; Corpuz MR; Prudente RY; Cooke TA; Bissonnette RP; Negro-Vilar A; Lamph WW
    Clin Cancer Res; 2004 Dec; 10(24):8656-64. PubMed ID: 15623650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.
    Yen WC; Lamph WW
    Prostate; 2006 Feb; 66(3):305-16. PubMed ID: 16245282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
    Hermann TW; Yen WC; Tooker P; Fan B; Roegner K; Negro-Vilar A; Lamph WW; Bissonnette RP
    Lung Cancer; 2005 Oct; 50(1):9-18. PubMed ID: 15993980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
    Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A
    J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
    Rodon J; Jacobs CD; Chu Q; Rowinsky EK; Lopez-Anaya A; Takimoto CH; Wakelee HA
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):825-34. PubMed ID: 22057853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma.
    Yen WC; Lamph WW
    Mol Cancer Ther; 2005 May; 4(5):824-34. PubMed ID: 15897247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
    Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
    Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma.
    Yen WC; Prudente RY; Lamph WW
    Breast Cancer Res Treat; 2004 Nov; 88(2):141-8. PubMed ID: 15564797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification.
    Tooker P; Yen WC; Ng SC; Negro-Vilar A; Hermann TW
    Cancer Res; 2007 May; 67(9):4425-33. PubMed ID: 17483357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
    Ihnat MA; Nervi AM; Anthony SP; Kaltreider RC; Warren AJ; Pesce CA; Davis SA; Lariviere JP; Hamilton JW
    Oncol Res; 1999; 11(7):303-10. PubMed ID: 10757444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
    Rigas JR; Dragnev KH
    Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.
    Dragnev KH; Petty WJ; Shah SJ; Lewis LD; Black CC; Memoli V; Nugent WC; Hermann T; Negro-Vilar A; Rigas JR; Dmitrovsky E
    Clin Cancer Res; 2007 Mar; 13(6):1794-800. PubMed ID: 17363535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
    Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS
    Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
    Wakelee HA; Takimoto CH; Lopez-Anaya A; Chu Q; Middleton G; Dunlop D; Ramlau R; Leighl N; Rowinsky EK; Hao D; Zatloukal P; Jacobs CD; Rodon J
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):563-71. PubMed ID: 22057855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.
    Singh RP; Mallikarjuna GU; Sharma G; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
    Clin Cancer Res; 2004 Dec; 10(24):8641-7. PubMed ID: 15623648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice.
    Shen H; Hu D; Du J; Wang X; Liu Y; Wang Y; Wei JM; Ma D; Wang P; Li L
    Eur J Pharmacol; 2008 Dec; 601(1-3):23-9. PubMed ID: 18983839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
    Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
    Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
    Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.